Neuropace Stock Market Value
| NPCE Stock | USD 15.67 0.18 1.16% |
| Symbol | Neuropace |
Will Health Care Equipment & Supplies sector continue expanding? Could Neuropace diversify its offerings? Factors like these will boost the valuation of Neuropace. Anticipated expansion of Neuropace directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neuropace data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.75) | Revenue Per Share | Quarterly Revenue Growth 0.299 | Return On Assets | Return On Equity |
Understanding Neuropace requires distinguishing between market price and book value, where the latter reflects Neuropace's accounting equity. The concept of intrinsic value - what Neuropace's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Neuropace's price substantially above or below its fundamental value.
It's important to distinguish between Neuropace's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neuropace should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Neuropace's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Neuropace 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Neuropace's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Neuropace.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in Neuropace on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding Neuropace or generate 0.0% return on investment in Neuropace over 90 days. Neuropace is related to or competes with Cerus, Rxsight, CVRx, 908 Devices, Brainsway, Senseonics Holdings, and Sight Sciences. NeuroPace, Inc. operates as a medical device company in the United States More
Neuropace Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Neuropace's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Neuropace upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.37 | |||
| Information Ratio | 0.1461 | |||
| Maximum Drawdown | 43.2 | |||
| Value At Risk | (4.26) | |||
| Potential Upside | 6.3 |
Neuropace Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neuropace's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Neuropace's standard deviation. In reality, there are many statistical measures that can use Neuropace historical prices to predict the future Neuropace's volatility.| Risk Adjusted Performance | 0.1391 | |||
| Jensen Alpha | 0.7323 | |||
| Total Risk Alpha | 0.345 | |||
| Sortino Ratio | 0.3468 | |||
| Treynor Ratio | 0.4263 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neuropace's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Neuropace February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1391 | |||
| Market Risk Adjusted Performance | 0.4363 | |||
| Mean Deviation | 3.04 | |||
| Semi Deviation | 1.86 | |||
| Downside Deviation | 2.37 | |||
| Coefficient Of Variation | 617.11 | |||
| Standard Deviation | 5.62 | |||
| Variance | 31.58 | |||
| Information Ratio | 0.1461 | |||
| Jensen Alpha | 0.7323 | |||
| Total Risk Alpha | 0.345 | |||
| Sortino Ratio | 0.3468 | |||
| Treynor Ratio | 0.4263 | |||
| Maximum Drawdown | 43.2 | |||
| Value At Risk | (4.26) | |||
| Potential Upside | 6.3 | |||
| Downside Variance | 5.61 | |||
| Semi Variance | 3.48 | |||
| Expected Short fall | (4.02) | |||
| Skewness | 4.73 | |||
| Kurtosis | 29.74 |
Neuropace Backtested Returns
Neuropace appears to be not too volatile, given 3 months investment horizon. Neuropace has Sharpe Ratio of 0.0911, which conveys that the firm had a 0.0911 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Neuropace, which you can use to evaluate the volatility of the firm. Please exercise Neuropace's Mean Deviation of 3.04, risk adjusted performance of 0.1391, and Downside Deviation of 2.37 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Neuropace holds a performance score of 7. The company secures a Beta (Market Risk) of 2.11, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Neuropace will likely underperform. Please check Neuropace's value at risk, kurtosis, market facilitation index, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether Neuropace's current price movements will revert.
Auto-correlation | 0.29 |
Poor predictability
Neuropace has poor predictability. Overlapping area represents the amount of predictability between Neuropace time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Neuropace price movement. The serial correlation of 0.29 indicates that nearly 29.0% of current Neuropace price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.29 | |
| Spearman Rank Test | 0.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.39 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neuropace is a strong investment it is important to analyze Neuropace's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuropace's future performance. For an informed investment choice regarding Neuropace Stock, refer to the following important reports:Check out Neuropace Correlation, Neuropace Volatility and Neuropace Performance module to complement your research on Neuropace. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Neuropace technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.